NEXIUM 24HR Drug Patent Profile

Which patents cover Nexium 24hr, and when can generic versions of Nexium 24hr launch?

Nexium 24hr is a drug marketed by Astrazeneca Lp and is included in two NDAs.

The generic ingredient in NEXIUM 24HR is esomeprazole magnesium. There is one drug master file entry for this compound. One hundred and fifteen suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nexium 24hr

A generic version of NEXIUM 24HR was approved as esomeprazole magnesium by MYLAN on August 2^nd, 2015.

Summary for NEXIUM 24HR

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	165
Patent Applications:	1,905
Drug Sales Revenues:	Drug sales revenues for NEXIUM 24HR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXIUM 24HR
What excipients (inactive ingredients) are in NEXIUM 24HR?	NEXIUM 24HR excipients list
DailyMed Link:	NEXIUM 24HR at DailyMed

See drug sales revenues for NEXIUM 24HR

Recent Clinical Trials for NEXIUM 24HR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Livzon Pharmaceutical Group Inc.	PHASE3
Bio-innova Co., Ltd	PHASE1
Alexandria University	Phase 3

See all NEXIUM 24HR clinical trials

Pharmacology for NEXIUM 24HR

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

Paragraph IV (Patent) Challenges for NEXIUM 24HR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXIUM 24HR	Delayed-release Capsules	esomeprazole magnesium	20 mg	204655		2014-04-24

US Patents and Regulatory Information for NEXIUM 24HR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Lp	NEXIUM 24HR	esomeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	204655-001	Mar 28, 2014		OTC	Yes	Yes
Astrazeneca Lp	NEXIUM 24HR	esomeprazole magnesium	TABLET, DELAYED RELEASE;ORAL	207920-001	Nov 23, 2015		OTC	Yes	Yes

International Patents for NEXIUM 24HR

See the table below for patents covering NEXIUM 24HR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	231719
Australia	681686
Australia	7198294
Brazil	9406941
Canada	2166483	NOUVELLE FORMULATION PHARMACEUTIQUE (NEW PHARMACEUTICAL FORMULATION)
China	1126946
Czech Republic	290323	Stabilní orální entericky potaľený přípravek, způsob jeho výroby a pouľití (Stable, oral, enteric coated preparation, process of its preparation and use)

Supplementary Protection Certificates for NEXIUM 24HR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1020461	C300482	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105
1020461	91870	Luxembourg
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
0984957	PA2011005	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957	C300483	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYFRAAT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20110524

NEXIUM 24HR (esomeprazole magnesium) — Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is NEXIUM 24HR’s market position and revenue model?

NEXIUM 24HR is an over-the-counter (OTC) and prescription branded product containing esomeprazole magnesium, a proton pump inhibitor (PPI). In the US, its market position is shaped by (1) long-term class demand for acid suppression, (2) competitive generic penetration for esomeprazole, and (3) brand retention through OTC format, dosing convenience, and historical prescribing familiarity.

Pricing and channel reality

• Prescription channel: Revenue is constrained by generic esomeprazole erosion as branded NEXIUM prescription share declines with patent/generic availability.
• OTC channel: OTC continues to support a premium brand price versus generics sold as store-brand PPIs, but it faces periodic promotional intensity from category competitors (other PPIs and H2 blockers).
• Formulation constraint: “24HR” branding tracks once-daily acid suppression expectations, which is a core purchase driver for consumer selection within OTC GI products.

Business model implications

• Brand spend discipline matters: Once generics dominate the base molecule, incremental branded revenue depends on maintaining shelf presence, trade terms, and DTC/field pull-through (for Rx) where applicable.
• Mix shift drives financial outcome: If OTC mix strengthens, brand economics can improve even when Rx declines, because OTC can carry a higher effective price per unit sold.

---

How do market dynamics affect Nexium 24HR demand?

1) Generic substitution is the dominant structural force

For established PPIs, the primary long-run dynamic is generic substitution of esomeprazole. That pressure reduces branded unit share and compresses pricing. As a result, branded financial trajectory tends to follow:

• Early branded durability driven by differentiation and clinician habits
• Then a steady decline in Rx share as generics expand
• Then stabilization via OTC branding if consumer awareness and convenience remain strong

2) OTC category competition sets promo intensity

OTC GI acid products are typically value-engineered and promo-driven around seasonal and promotion calendar cycles. Nexium 24HR competes against:

• Other OTC PPIs (class competitors with similar onset and duration claims)
• H2 blockers in overlapping “occasional heartburn” segments
• Store brands and private labels that reduce consumer willingness to pay

3) Regulatory and labeling constraints impact claim-driven growth

OTC PPIs have defined indications and usage limitations that reduce growth optionality. Growth tends to come from:

• Expanded distribution access (shelf and ecommerce)
• Maintaining compliance of consumer messaging with labeling
• Leveraging “complete 24-hour coverage” style positioning within allowed marketing claims

---

What is the financial trajectory pattern for Nexium 24HR (brand economics under generic pressure)?

Because branded NEXIUM revenues are influenced by both Rx and OTC, the financial trajectory generally follows a two-phase curve:

Phase 1: Prescription-led brand peak

• Branded revenues grow or remain robust when fewer generics compete.
• Financial trajectory is sensitive to managed care contracting, formulary status, and payer step therapy.

Phase 2: Sustained decline with OTC ballast

• Generic penetration lowers net price and share in Rx.
• OTC can partially offset decline if brand trust and shelf performance persist.

Observed trajectory logic (what moves the P&L)

Key levers that determine whether NEXIUM 24HR stabilizes or keeps sliding:

• Effective net price (gross price less rebates and trade spend)
• Unit share (store and online shelf placement)
• OTC category growth (household adoption of daily acid suppression vs intermittent relief)
• Competitive promo cycles (especially during seasonal heartburn and back-to-routine periods)

---

What does “NEXIUM 24HR” vs “esomeprazole generics” imply for margins and sustainability?

Brand premium is not permanent, but it is recurring

Even with generic pressure, branded PPIs often sustain a margin advantage where:

• Consumers perceive better outcomes or convenience
• Retailers maintain brand-endorsed shelf space
• Trade terms support a stable distribution footprint

Generic price ceilings

Generics set a pricing floor in many channels. That compresses branded gross margin over time, making branded profitability more dependent on:

• Cost discipline (marketing and supply chain)
• Share protection actions
• OTC mix optimization

---

Which competitive forces most directly shape Nexium 24HR performance?

Competitive set

NEXIUM 24HR competes within the OTC and Rx PPI universe. Competitive pressure typically comes from:

• Same-class PPIs with similar once-daily positioning
• Payers shifting to generics post formulary churn
• Retail promo calendars that influence OTC conversion

Switching dynamics

Switching is frequent after generic entry because:

• The active ingredient is the same (esomeprazole)
• Substitution is easier for consumer products where differentiation is less about molecule performance and more about price, pack size, and claim confidence

---

How do US regulatory and channel structures influence sales volatility?

OTC accessibility lowers friction, but also raises price competition

OTC availability supports steady demand, but it also invites:

• Private label competition
• Aggressive retailer promotions
• Periodic shifts in consumer basket mix

Rx channel depends on formulary rules

Where branded Rx remains present, performance depends on:

• Step therapy policies
• Formulary tiering (generic preferred)
• Prior authorization and quantity limits

These policies can cause abrupt volume declines even when total class demand grows.

---

What is the likely financial trajectory for NEXIUM 24HR over the next several years?

A branded PPI like NEXIUM 24HR typically trends toward:

• Long-run volume pressure from generic substitution
• Net sales stabilization via OTC presence
• Gradual margin compression from pricing pressure and promotional intensity

Net effect: a slower decline or plateau in top-line is possible if OTC mix holds up; otherwise, declines continue with branded unit share loss. The decisive determinant is whether OTC share and effective pricing remain resilient against competitor promo cycles.

---

Key Takeaways

• NEXIUM 24HR’s demand is structurally constrained by generic substitution for esomeprazole, which drives long-term Rx erosion.
• OTC format supports stabilization, but it also increases exposure to retail promotion intensity and private label competition.
• Financial trajectory is dominated by net price and mix, not by fundamental expansion of the PPI class alone.
• Sustainability depends on share protection in OTC channels and cost discipline as pricing pressure intensifies.

---

FAQs

1) Is NEXIUM 24HR growth driven by new clinical breakthroughs?

No. Its market behavior is primarily driven by channel mix (Rx versus OTC) and pricing power under generic substitution, not by new mechanism-based differentiation.

2) Why does the 24-hour branding matter economically?

It aligns with consumer purchase logic for once-daily convenience and “duration” expectations, supporting shelf conversion even when active ingredient equivalence exists across competitors.

3) What most often causes branded revenue drops for NEXIUM in the US?

Formulary and step-therapy shifts that favor generics, plus trade and promotional dynamics that compress net pricing.

4) Can OTC fully offset Rx losses for NEXIUM 24HR?

It can offset only part of Rx erosion. Sustained OTC performance depends on maintaining effective price and share amid heavy retail competition.

5) Where is the biggest risk to NEXIUM 24HR profitability?

Margin compression from ongoing promotional intensity and pricing pressure, especially as competitor OTC PPIs and private labels compete for share.

---

References (APA)

[1] Eli Lilly and Company. (n.d.). Nexium 24HR (esomeprazole magnesium) product information. https://www.nexium24hr.com/
[2] FDA. (n.d.). Drug products and databases (labeling/approval information for esomeprazole products). https://www.accessdata.fda.gov/